ArticleMolecular therapy : the journal of the American Society of Gene Therapy2010
Safer CARS.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Phase I/II clinical trial on the safety and preliminary efficacy of donor-derived anti-leukemia cytotoxic T lymphocytes for the prevention of leukemia relapse in children given haploidentical hematopoietic stem cell transplantation: study rational and design.Frontiers in immunology · 2025Article
- ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors.Nature immunology · 2023Article
- CAR Based Immunotherapy of Solid Tumours-A Clinically Based Review of Target Antigens.Biology · 2023Review
- Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.Nano letters · 2020Article
- Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.Frontiers of medicine · 2019Article
- Article
- Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.International journal of molecular sciences · 2017Article
- The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.Cancer gene therapy · 2017Article
- Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors.Molecular therapy oncolytics · 2016Article
- CAR T-cell immunotherapy: The path from the by-road to the freeway?Molecular oncology · 2015Review
- Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.Oncotarget · 2015Article
- Genetically modified T cells in cancer therapy: opportunities and challenges.Disease models & mechanisms · 2015Review
- Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.Leukemia · 2015Review
- A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer.Drug design, development and therapy · 2015Review
- Roadblocks to success for RNA CARs in solid tumors.Oncoimmunology · 2014Article
- Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.Cancer immunology research · 2014Article
- Gene and cell therapy for children--new medicines, new challenges?Advanced drug delivery reviews · 2014Review
- Engineered T cells for cancer treatment.Cytotherapy · 2014Review
- Impact of T cell selection methods in the success of clinical adoptive immunotherapy.Cellular and molecular life sciences : CMLS · 2014Article
- Is cancer gene therapy an empty suit?The Lancet. Oncology · 2013Review
Corrections and comments
- Commented on by
- Comment on
- Comment on
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.